Inicio > COCO MARTIN, ROSA MARIA

COCO MARTIN, ROSA MARIA

CATEDRATICOS DE UNIVERSIDAD
Cirugía, Oftalmología, Otorrinolaringología y Fisioterapia
Grupo de Retina
 
rosamcoco@uva.es

Índice H en Scopus: 18
 

[][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=80421]], camposKey:1757-6512 2023-12-01 Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=80681]], camposKey:0275-004X 2023-08-01 INTRAOCULAR EMULSION OF SILICONE OIL (ITEMS) GRADING SYSTEM: An Evidence-Based Expert-Led Consensus13701376, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75910]], camposKey:2077-0383 2023-03-01 Does PLEX® Elite 9000 OCT Identify and Characterize Most Posterior Pole Lesions in Highly Myopic Patients?00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75707]], camposKey:2077-0383 2023-03-01 Impact of COVID-19 Confinement on Quality of Life of Patients with Age-Related Macular Degeneration: A Two-Wave Panel Study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=78307]], camposKey:0365-6691 2023-01-01 Evaluación de signos tomográficos no exudativos en casos de degeneración macular asociada a la edad de tipo exudativo276280, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75911]], camposKey:0365-6691 2023-01-01 Evaluation of non-exudative tomographic signs in cases of exudative age-related macular degeneration Evaluación de signos tomográficos no exudativos en casos de degeneración macular asociada a la edad de tipo exudativo00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=80682]], camposKey:0365-6691 2023-01-01 Protocol for the treatment of cystoid macular edema secondary to retinitis pigmentosa and other inherited retinal dystrophies Protocolo de tratamiento del edema macular quístico asociado a retinosis pigmentaria y otras distrofias hereditarias de la retina00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75164]], camposKey:0030-3747 2022-12-01 Pathophysiology of Age-Related Macular Degeneration: Implications for Treatment615636, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=72043]], camposKey:0014-4835 2022-06-01 Hair cortisol level as a molecular biomarker in retinitis pigmentosa patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75165]], camposKey:1170-229X 2022-05-01 Modifiable Determinants of Satisfaction with Intravitreal Treatment in Patients with Neovascular Age-Related Macular Degeneration355366, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65211]], camposKey:1745-6673 2021-11-12 Long-term visual pathway alterations after elemental mercury poisoning: report of a series of 29 cases00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65214]], camposKey:2045-2322 2021-01-12 Intraocular toxicity caused by MEROCTANE perfluorocarbon liquid00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65213]], camposKey:1177-5483 2021-01-01 Descriptive Study of a Cohort of 488 Patients with Inherited Retinal Dystrophies10751084, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=59768]], camposKey:1673-5374 2021-01-01 Intravitreal stem cell paracrine properties as a potential neuroprotective therapy for retinal photoreceptor neurodegenerative diseases16311638, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65212]], camposKey:0146-0404 2021-01-01 Phenotypic differences in the PRPH2 mutation in members of the same family assessed with OCT and OCTA00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=58381]], camposKey:1755-375X 2021-01-01 Silicone microbubbles after anti-vascular endothelial growth factor injections in patients with wet age-related macular degeneration: incidence, quantification and secondary optical coherence tomography artfacts00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65215]], camposKey:2090-004X 2020-09-16 Early Detection of Incipient Retinal Pigment Epithelium Atrophy Overlying Drusen with Fundus Autofluorescencevs. Spectral Domain Optical Coherence Tomography00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56673]], camposKey:0721-832X 2020-06-20 Progression of myopic maculopathy in a Caucasian cohort of highly myopic patients with long follow-up: a multistate analysis00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65216]], camposKey:0146-0404 2020-06-01 Influence of non-mydriasis on optical coherence tomography imaging quality in patients with Retinitis Pigmentosa00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=65217]], camposKey:0146-0404 2020-06-01 Is the new ISO 16672.2: 2019 the best prevention to avoid future cases of acute intraocular toxicity by perfluorocarbon liquids?00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=51256]], camposKey:0273-2300 2020-01-01 Chemical compounds causing severe acute toxicity in heavy liquids used for intraocular surgery1045270, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52553]], camposKey:1673-5374 2020-01-01 Intravitreal stem cell paracrine properties as a potential neuroprotective therapy for retinal photoreceptor neurodegenerative diseases16311638, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=66397]], camposKey:1661-6596 2020-01-01 Matrix metalloproteinases in age-related macular degeneration (Amd)132, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=63262]], camposKey:2073-4425 2020-01-01 PRPH2-Related Retinal Diseases: Broadening the Clinical Spectrum and Describing a New Mutation7730, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=50858]], camposKey:1120-6721 2020-01-01 Reliability of colour perimetry to assess macular pigment optical density in age-related macular degeneration14801486, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43077]], camposKey:0007-1161 2019-01-01 Acute retinal toxicity associated with a mixture of perfluorooctane and perfluorohexyloctane: Failure of another indirect cytotoxicity analysis4954, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43073]], camposKey:0146-0404 2019-01-01 Chemical considerations regarding the H-value methodology and its relation with toxicity determination33633364, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53048]], camposKey:0146-0404 2019-01-01 Clinical characteristics of proven acute intraocular toxicity by perfluorocarbon liquids (PFCL) used in retinal surgery00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53049]], camposKey:0146-0404 2019-01-01 Cytotoxicity evaluation of toxic substances identified in recent reported toxic lots of perfluorocarbon liquids used in intraocular surgery in patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=50859]], camposKey:0141-9382 2019-01-01 Development and evaluation of a head-mounted display system based on stereoscopic images and depth algorithms for patients with visual impairment4956, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53047]], camposKey:0146-0404 2019-01-01 Low Visual Pathway Alterations and Neurological Toxic Effects after Acute Mercury Poisoning in Zinc Manufacturer Workers00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53607]], camposKey:0275-004X 2018-04-01 Diagnostic and Therapeutic Challenges849853, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11666]], camposKey:2045-2322 2018-01-01 Comparison between direct contact and extract exposure methods for PFO cytotoxicity evaluation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52974]], camposKey:0146-0404 2018-01-01 Toxicity of an endotamponade made by a mixture of perfluorooctane and perfluorohexyloctane evaluated by a new cytotoxicity method00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39306]], camposKey:0146-0404 2017-06-01 Acute retinal toxic damage by AlaOcta (R) a liquid perfluorooctane liquid used in retinal detachment surgery. Clinical picture and functional consequences00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10084]], camposKey:0275-004X 2017-01-01 Acute retinal damage after using a toxic perfluoro-octane for vitreo-retinal surgery11401151, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10088]], camposKey:1793-5458 2017-01-01 Control of disability glare by means of electrochromic filtering glasses: A pilot study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10055]], camposKey:0950-222X 2017-01-01 Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review273285, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39307]], camposKey:0146-0404 2017-01-01 Perfluoro-n-octane cytotoxicity in human retinal pigment epithelial cell culture00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39308]], camposKey:0146-0404 2017-01-01 Perfluoro-n-octane cytoxicity in porcine neuroretina organotypic culture00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10063]], camposKey:1471-2415 2017-01-01 Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11667]], camposKey:0365-6691 2017-01-01 The acute toxicity problem with some perfluorooctanes El problema de la toxicidad aguda de algunos perfluoro-octanos455457, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52982]], camposKey:0022-3573 2016-01-01 Clinical Characterization and Frequency of Observation of Hereditary Retinal Diseases: Multicentric Study in Panama in 2012-2013618630, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10094]], camposKey:1046-6673 2016-01-01 Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases13051311, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52945]], camposKey:2167-8707 2016-01-01 Patient participation in the development of a clinical guideline for inherited retinal dystrophies691697, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10061]], camposKey:2167-8707 2016-01-01 Patient participation in the development of a clinical guideline for inherited retinal dystrophies (vol 4, pg 691, 2016)11, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10049]], camposKey:0030-3755 2016-01-01 Perfluorocarbon Liquids Toxicity: A Sanitary Alert6363, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39310]], camposKey:0146-0404 2016-01-01 PREDICTIVE MODELS OF LONG-TERM ANATOMIC OUTCOME IN EXUDATIVE AMD TREATED WITH AS-NEEDED RANIBIZUMAB00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10068]], camposKey:0146-0404 2016-01-01 Visual alterations in a cohort of young male patients with acute/subacute intoxication with mercury vapor00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10067]], camposKey:1471-2350 2016-01-01 X-Linked retinoschisis associated to a novel intragenic microdeletion: case report00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49611]], camposKey:1755-375X 2015-01-01 BAX and BCL-2 polymorphisms, as predictors of proliferative vitreoretinopathy development in patients suffering retinal detachment: The Retina 4 project00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10093]], camposKey:2090-004X 2015-01-01 Loss of Visual Acuity after Successful Surgery for Macula-On Rhegmatogenous Retinal Detachment in a Prospective Multicentre Study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10104]], camposKey:0007-1161 2015-01-01 Predicting proliferative vitreoretinopathy: temporal and external validation of models based on genetic and clinical variables4148, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10064]], camposKey:0146-0404 2015-01-01 PREDICTIVE FACTORS OF VISUAL IMPROVEMENT IN EXUDATIVE AMD PATIENTS AFTER 4 YEARS OF AS NEEDED RANIBIZUMAB TREATMENT00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39311]], camposKey:0146-0404 2015-01-01 WAVEFRONT ANALYSIS OF HIGHER-ORDER ABERRATIONS IN PATIENTS WITH HIGH MYOPIA00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10089]], camposKey:1471-2415 2014-01-01 Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49491]], camposKey:2168-6165 2014-01-01 Growth of geographic atrophy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration528534, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10054]], camposKey:1471-2415 2014-01-01 Management of significant reactivation of old disciform scars in wet Age-Related Macular Degeneration00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53606]], camposKey:0146-0404 2013-06-01 Predictive Factors of Reading Performance Post Reading Rehabilitation Program in Central Field Loss Patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10103]], camposKey:0146-0404 2013-01-01 A Genetic Case-Control Study Confirms the Implication of SMAD7 and TNF Locus in the Development of Proliferative Vitreoretinopathy16651678, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10100]], camposKey:0030-3755 2013-01-01 A New Manual Retinal Thickness Measurement Protocol to Evaluate High Myopia Patients121125, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10048]], camposKey:2090-004X 2013-01-01 Autofluorescence Images with Carl Zeiss versus Topcon Eye Fundus Camera: A Comparative Study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52946]], camposKey:0365-6691 2013-01-01 Evolucion clinica de pacientes con degeneracion macular asociada a la edad de tipo exudativo-hemorragico tratados con ranibizumab. Estudio Eye2Eye. Clinical course of patients with exudative-haemorrhagic age-related macular degeneration treated with ranibizumab. Eye2Eye study.216222, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10098]], camposKey:0275-004X 2013-01-01 External validation of existing formulas to predict the risk of developing proliferative vitreoretinopathy: The retina 1 project; Report 515191527, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53046]], camposKey:1927-6990 2013-01-01 General Practitioners' knowledge gaps regarding Age Related Macular Degeneration and effectiveness of their e-learning training3747, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10083]], camposKey:0271-3683 2013-01-01 Ocular Pain After Intravitreal Injection278282, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10101]], camposKey:0161-6420 2013-01-01 The p53 Codon 72 Polymorphism (rs1042522) Is Associated with Proliferative Vitreoretinopathy The Retina 4 Project623628, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10102]], camposKey:1932-6203 2013-01-01 The T309G MDM2 Gene Polymorphism Is a Novel Risk Factor for Proliferative Vitreoretinopathy00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52947]], camposKey:0146-0404 2013-01-01 Visual loss in retinal detachment and macula-on after successful surgery, Retina 1 project00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10092]], camposKey:1120-6721 2012-01-01 A propensity score matching application: indications and results of adding scleral buckle to vitrectomy: The Retina 1 Project: Report 3244253, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10066]], camposKey:0308-0110 2012-01-01 E-learning strategies to improve general practitioners' knowledge of age-related macular degeneration517518, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10085]], camposKey:0030-3755 2012-01-01 Pathology Associated with Optical Coherence Tomography Macular Bending due to either Dome-Shaped Macula or Inferior Staphyloma in Myopic Patients712, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10095]], camposKey:0146-0404 2012-01-01 Relevance of Complement Factor H-Related 1 (CFHR1) Genotypes in Age-Related Macular Degeneration10871094, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10077]], camposKey:0030-3755 2012-01-01 Retinal Pigment Epithelium Tears in Age-Related Macular Degeneration Treated with Antiangiogenic Drugs: A Controlled Study with Long Follow-Up7883, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53608]], camposKey:0065-2598 2012-01-01 SJOGREN-LARSSON SYNDROME344350, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53050]], camposKey:0146-0404 2012-01-01 The Impact Of Low Vision In The Activities Of Daily Living And Emotional State Of Elderly People00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52969]], camposKey:2090-5688 2012-01-01 Variations in Functional and Anatomical Outcomes and in Proliferative Vitreoretinopathy Rate along a Prospective Collaborative Study on Primary Rhegmatogenous Retinal Detachments: The Retina 1 Project-Report 4.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10097]], camposKey:1755-375X 2011-01-01 Genetic association study of age-related macular degeneration in the Spanish population00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=49502]], camposKey:0365-6691 2011-01-01 Genetics and ARMD: from the laboratory to the consulting room101102, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10086]], camposKey:0161-6420 2011-01-01 Sjogren-Larsson Syndrome21012102, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11669]], camposKey:1177-5467 2011-01-01 Training and professional profile of retinologists in Spain: Retina 2 project, Report 4483490, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10096]], camposKey:0161-6420 2010-01-01 A Strong Genetic Association between the Tumor Necrosis Factor Locus and Proliferative Vitreoretinopathy: The Retina 4 Project24172423, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40837]], camposKey:1938-2375 2010-01-01 Benign fleck retinal findings on multifocal ERG, microperimetry, and OCT.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=50860]], camposKey:1560-2133 2010-01-01 Choroidal neovascularisation in punctate inner choroidopathy: therapeutic options.1928, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11670]], camposKey:0275-004X 2010-01-01 Diagnostic and therapeutic challenges13111315, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10058]], camposKey:1120-6721 2010-01-01 PRPH2 (Peripherin/RDS) mutations associated with different macular dystrophies in a Spanish population: a new mutation724732, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53051]], camposKey:0146-0404 2009-01-01 Development of Electrochromic Filters for Visual Rehabilitation00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11671]], camposKey:0365-6691 2009-01-01 Formación y actividad clínica de los retinólogos en españa: Un primer acercamiento. Proyecto retina 2. Análisis descriptivo Training and clinical activity of Spanish retinologists: A preliminary approach. Retina 2 project. Descriptive analysis7584, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53604]], camposKey:0275-004X 2008-07-01 Diagnostic and therapeutic challenges10181022, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53052]], camposKey:0146-0404 2008-01-01 Analysis of Peripherin-rds in Isolated Cases and Spanish Families Presenting Different Macular Dystrophies00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53042]], camposKey:0146-0404 2008-01-01 Anatomical and Functional Outcomes After Surgery for Primary Rhegmatogenous Retinal Detachments (RD) in Phakic and Pseudophakic Patients. Preliminary Results of a Multicentric Prospective Study: The Retina 1 Project52405240, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10082]], camposKey:0300-7995 2008-01-01 Burden of illness of bilateral neovascular age-related macular degeneration in Spain21032111, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10072]], camposKey:0275-004X 2008-01-01 Diagnostic and therapeutic challenges174179, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10069]], camposKey:0007-1161 2008-01-01 Non-complicated retinal detachment management: variations in 4 years. Retina 1 project; report 1523525, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52967]], camposKey:1935-1089 2008-01-01 Oct findings in torpedo maculopathy109111, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10090]], camposKey:0007-1161 2008-01-01 Surgical outcomes for primary rhegmatogenous retinal detachments in phakic and pseudophakic patients: the Retina 1 Project - report 2378382, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53053]], camposKey:0146-0404 2008-01-01 Training Reading Performance Might Improve Depression in Low Vision Patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10070]], camposKey:1542-8877 2007-01-01 Atypical myopic retinoschisis157159, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11673]], camposKey:0161-6420 2007-01-01 Complement Factor H00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53605]], camposKey:0161-6420 2007-01-01 Complement factor H193193, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=58179]], camposKey:0365-6691 2007-01-01 El impacto de la Ley de Dependencia en los pacientes con baja visión393394, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10081]], camposKey:0927-3948 2007-01-01 Photodynamic therapy for subfoveal and juxtafoveal choroidal neovascularization associated with punctate inner choroidopathy2729, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=53041]], camposKey:0146-0404 2007-01-01 Telephone Satisfaction Questionnaire for Evaluation the Efficacy of a Vision Rehabilitation Treatment35593559, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11672]], camposKey:0365-6691 2007-01-01 The impact of the dependency law in low vision patients El impacto de la ley de dependencia en los pacientes con baja visión393394, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10091]], camposKey:0030-3747 2006-01-01 Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening193200, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10099]], camposKey:1395-3907 2006-01-01 Photodynamic therapy in subfoveal and juxtafoveal idiopathic and postinflammatory choroidal neovascularization743748, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=58180]], camposKey:0365-6691 2005-01-01 Monocromatismo de conos azules ligado a X: Una familia afecta3540, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11674]], camposKey:0531-5131 2005-01-01 Reading comparative study: Electronic vs. conventional devices8587, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11675]], camposKey:0365-6691 2005-01-01 X-linked blue cone monochromatism. A familial case report Monocromatismo de conos azules ligado a X. Una familia afecta.3540, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11676]], camposKey:0365-6691 2004-01-01 Corneal epithelial complications after vitrectomy: a retrospective study Complicaciones corneales epiteliales de las vitrectomías: estudio retrospectivo.155161, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=56674]], camposKey:0146-0404 2003-05-01 Clinical and surgical features of retinal shortening: The most severe and less recognized form of proliferative vitreoretinopathy (PVR)00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10075]], camposKey:0146-0404 2003-01-01 Clinical and surgical features of retinal shortening: The most severe and less recognized form of proliferative vitreoretinopathy (PVR)29790, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11677]], camposKey:0365-6691 2003-01-01 Retinal shortening: the most severe form of proliferative vitreoretinopathy (PVR). Acortamiento retiniano: la forma más grave de la vitreorretinopatía proliferante (VRP).653657, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=13961]], camposKey:0365-6691 2003-01-01 Roturas retinianas iatrogénicas en las vitrectomías: estudio retrospectivo487491, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10087]], camposKey:1059-7794 2002-01-01 Analysis of ABCA4 in Mixed Spanish Families Segregating Different Retinal Dystrophies00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11679]], camposKey:0365-6691 2002-01-01 Functional improvement after vision rehabilitation in low monocular vision after myopic macular degeneration and retinal detachment Mejora funcional tras la rehabilitación visual en una paciente con visión monocular deficitaria debido a degeneración macular miópica y desprendimiento de retina.9598, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10071]], camposKey:0002-9394 2002-01-01 Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss341349, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=44578]], camposKey:0365-6691 2002-01-01 Mejora funcional tras la rehabilitación visual en una paciente con visión monocular deficitaria debido a degeneración macular miópica y desprendimiento de retina9597, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10079]], camposKey:1018-4813 2002-01-01 Mutation and haplotype analysis of ABCA4 in mixed Spanish families and implication of this gene in a pattern dystrophy phenotype.237237, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=8812]], camposKey:0146-0404 2002-01-01 Study of the efficacy of a new electronic device for the ARMD: A new therapeutic option00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11680]], camposKey:0365-6691 2001-01-01 First results of the IOBA low vision unit Primeros resultados de la Unidad de Baja Visión del IOBA.719722, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39313]], camposKey:0146-0404 2001-01-01 Fundus autofluorescence in patients with age-related macular degeneration and high risk characteristics.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=67278]], camposKey:0365-6691 2000-01-01 Comentarios sobre el artículo titulado «Fotocoagulación en rejilla en la degeneración macular asociada a la edad (DMAE). Primeros resultados»213214, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40839]], camposKey:0365-6691 2000-01-01 Comments on Grid photocoagulation in age-related macular degeneration (ARMD). Preliminary results Comentarios sobre el artículo titulado: Fotocoagulación en rejilla en la degeneración macular asociada a la edad (DMAE). Primeros resultados.213214, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=11681]], camposKey:0002-9297 2000-01-01 Further evidence for an association of ABCR alleles with age-related macular degeneration487491, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10057]], camposKey:1080-7683 2000-01-01 Pharmacokinetics of 0.5 mg of a single and a multiple dose of intravitreal vancomycin in infected rabbit eyes373381, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10078]], camposKey:0146-0404 2000-01-01 The degree of symmetry of fundus autofluorescence in early age-related maculopathy.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10073]], camposKey:1080-7683 1998-01-01 Pharmacokinetics of intravitreal vancomycin in normal and infected rabbit eyes555563, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10074]], camposKey:0146-0404 1997-01-01 Changes in fundus autofluorescence in age related maculopathy using cSLO in patients in a laser photocoagulation trial00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10059]], camposKey:0146-0404 1997-01-01 Efficacy of a new regime of intravitreal vancomycin in the treatment of endophthalmitis rabbit eyes51975197, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=71301]], camposKey:0146-0404 1996-02-15 Pharmacokinetics of a multiple regimen of 0.5 mg of vancomycin in endophthalmic rabbit eyes35733573, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43956]], camposKey:0365-6691 1996-01-01 Estudio citológico del vítreo en las vitrectomías: diferencias entre vitreorretinopatía proliferante y retinopatía diabática proliferante197204, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=1892]], camposKey:0021-9673 1996-01-01 High-performance liquid chromatographic determination of vancomycin in rabbit serum, vitreous and aqueous humour after intravitreal injection of the drug231238, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=40841]], camposKey:0146-0404 1996-01-01 Pharmacokinetics of a multiple regimen of 0.5 mg of vancomycin in endophthalmic rabbit eyes00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39314]], camposKey:0146-0404 1995-01-01 DISTRIBUTION OF AGE-RELATED LENS OPACITIES IN A SPANISH POPULATION-SAMPLE00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39317]], camposKey:0146-0404 1995-01-01 INTRAVITREAL PHARMACOKINETICS OF 0.5 AND 1 MG OF VANCOMYCIN IN ENDOPHTHALMIC RABBIT EYES00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10062]], camposKey:0146-0404 1995-01-01 VALUE OF VITREOUS CYTOLOGY IN THE DIAGNOSIS OF VITREORETINAL DISEASES00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10052]], camposKey:0146-0404 1995-01-01 Vitreous levels of lomefloxacin after intravenous injection in the rabbit. Sample extraction with a perfused rabbit eye model00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=10060]], camposKey:0146-0404 1994-01-01 PHARMACOKINETICS OF INTRAVITREAL VANCOMYCIN IN INFECTED AND UNINFECTED RABBIT EYES19071907][CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=11089]},camposKey: 97 103 Calidad de vida y efectos psicosociales en baja visión 8498358493Manual de Baja Visión y Rehabilitación Visual 1 null Editorial Médica Panamericana , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=22172]},camposKey: 3 8 Concepto de baja visión, discapacidad visual y rehabilitación visual: profesionales de la visión 8498358493Manual de Baja Visión y Rehabilitación Visual 1 null Editorial Médica Panamericana , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=3605]},camposKey: 3 8 Concepto de baja visión, discapacidad visual y rehabilitación visual. Profesionales de la visión 8498358493Manual de Baja Visión y Rehabilitación Visual 1 null Editorial Médica Panamericana , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19151]},camposKey: 179 185 Enfermedades hereditarias difusas de los fotoreceptores 978-84-9113-564-7Manual de retina SERV 2 2019-01-01 Elsevier España, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19670]},camposKey: 460 470 Capítulo 25. Cirugía Vitreorretiniana en los traumatismos oculares. Sección 25E. Tamponadores, manipuladores y tinciones en la cirugía del traumatismo ocular 978-84-89085-68-8Traumatología ocular 1 2018-01-01 Sociedad Española de Oftalmología, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19669]},camposKey: 97 99 Endoftalmitis luética en paciente con implante intravítreo de dexametasona 978-84-16269-41-9Casos clínicos en oftalmología II: Problemas diagnósticos en patología retinocoroidea 1 2018-01-01 Euromedice Vivactis, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19153]},camposKey: 158 163 Distrofias Retinianas 8490221529Manual de retina 1 2013-03-01 Elsevier , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=31170]},camposKey: 161 163 Enfermedades hereditarias difusas de los fotorreceptores: Distrofias progesivas de conos y distrofias progresivas de conos y bastones 8490221529Manual de retina 1 2013-03-01 Elsevier , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=31169]},camposKey: 158 161 Enfermedades hereditarias difusas de los fotorreceptores: Retinitis pigmentosa 8490221529Manual de retina 1 2013-03-01 Elsevier , CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19155]},camposKey: 89 94 Estudios descriptivos 978-84-89085-51-0De la idea a la publicación científica. Manual de investigación clínica 1 2013-01-01 MacLine, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19109]},camposKey: 687 718 New electro-optic and display technology for visually disabled people 9781466639867Handbook of Research on ICTs for Human-Centered Healthcare and Social Care Services 1 2013-01-01 Medical Information Science Reference, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19158]},camposKey: 337 356 Distrofias maculares 978-84-89085-44-2PATOLOGÍA Y CIRUGÍA DE LA MÁCULA 1 2010-01-01 Sociedad Española de Oftalmología, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=19157]},camposKey: 319 335 Enfermedades Hereditarias de los Conos 978-84-89085-44-2PATOLOGÍA Y CIRUGÍA DE LA MÁCULA 1 2010-01-01 Sociedad Española de Oftalmología, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=26004]},camposKey: 816 817 Mejora en la calidad de vida de personas deficientes visuales mediante rehabilitación visual 8481961442Apoyos, autodeterminación y calidad de vida 1 2001-01-01 Amarú ][][Llibres{id=com.sigma.fs3.argos.domain.gpc.GpcLlibresPK[ifcactivitat=LLI, ifccomptador=101733],camposKey=978-84-9835-849-0Manual de baja visión y rehabilitación visual 1 2015-01-01 Editorial Médica Panamericana}][][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62094]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62894]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62094]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=62894]]][][][com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145638966]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145638169]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145640539]], com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145636997]]][][][][][][][][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@f115813][][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f6f22, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f769f, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7051, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7756, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f75f3, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f6da2, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3bf147, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7b8a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f6c43, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7c27, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@3751e6, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7d41, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f710c, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f6d33, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7e2a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7839, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f71f8, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f70aa, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f79a7, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f717e, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7981, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f71a5, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7865, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f76f0, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7c2b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7e65, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f80f7, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f722c, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373664, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7c6c, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7422, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7f4c, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f78a4, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f70d7, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7f10, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7563, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7594, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373689, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373a70, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f71b5, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7ba2, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@373aab, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7de5, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f6d8b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7518, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7cdc, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7d17, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7150, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f6edd, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f78fd, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f6be7, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7085, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f6d9a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7081, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7895, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f6fd4, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f71d0, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f6cd1, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7078, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@5f7184, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372257][][][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=60884]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.gpc.GpcEstadesForaPK[ifcactivitat=ESF, ifccomptador=60884]]][][com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1005]], com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1154]]][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@465521], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4662cc], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@46595b], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@467c00], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45eee8], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@467c25], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45eea9], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5be73a], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@414d42], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41335c], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413397], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5be6a4], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45eeaa], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45eeab], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413bdc], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4136a9], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45eeac], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5be697], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@460794], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41235e], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@45f45f]][][CatedrasConvenios{id=22, codigoPersona=com.sigma.fs3.argos.domain.gpc.PersonalGPC[ifcidPers=23489], codigoTipo=CAT, codigoContable=null, titulo=CÁTEDRA ZEISS EN LA UNIVERSIDAD DE VALLADOLID, fechaInicio=2017-09-01, fechaFin=null, importe=12100.0, visiblePortal=1, visibleCvn=1, visibleMemoria=1, validado=S}][][][][com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@1581e, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@155c3, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@1531c, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@142e2, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@14803, com.sigma.fs3.argos.domain.gpc.altres.ProjecteInnovacio@1480d][]

PUBLICACIONES

Artículos de revista (139)

Pastor J.C.; Pastor-Idoate S.; Lopez-Paniagua M.; Para M.; Blazquez F.; Murgui E.; Garcia V.; Coco-Martin R.M. Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy . STEM CELL RESEARCH & THERAPY 2023; 14(1).

Enlace a la publicación
Ver Todos

Libros (1)

Coco Martin, Maria Begoña, dir.; Herrera Medina, Joaquin, dir.; Lazaro Yague, Jose Alberto, coord.; Cuadrado Asensio, Ruben, coord. Manual de baja visión y rehabilitación visual. Editorial Médica Panamericana; 2015.
Ver Todos

Capítulos de libros (14)

Alamo Martin, Maria Teresa del; Coco Martin, Rosa; Flores Lucas, Valle. Calidad de vida y efectos psicosociales en baja visión. En: -. Manual de Baja Visión y Rehabilitación Visual. Editorial Médica Panamericana p. 97-103.


Ver Todos
 

AYUDA A LA INVESTIGACIÓN

Proyectos (21)

RED DE ENFERMEDADES INFLAMATORIAS. Equipo Investigadores: COCO MARTIN, ROSA MARIA (IP); PASTOR IDOATE, SALVADOR (IP); SOBAS ABAD, EVA MARIA; BLAZQUEZ ARAUZO, FRANCISCO; FERNANDEZ BUENO, IVAN; SANABRIA RUIZ COLMENARES, MARIA ROSA; SRIVASTAVA, GIRISH KUMAR; USATEGUI MARTIN, RICARDO; MALDONADO LÓPEZ, MIGUEL JOSÉ; COCO MARTIN, ROSA MARIA; PASTOR IDOATE, SALVADOR; LOPEZ MIGUEL, ALBERTO. Personal Contratado: GUANTAY SOLIS, CARLA DANIELA; GALINDO CABELLO, NADIA REGINA. RD21/0002/0017. Entidades Participantes: UNIVERSIDAD DE VALLADOLID (UVa). Entidades Financiadoras: UNIÓN EUROPEA.-NEXT GENERATION UE, PLAN DE RECUPERACIÓN, TRANSFORMACIÓN Y RESILIENCIA, MICINN. MINISTERIO DE CIENCIA E INNOVACIÓN , INSTITUTO DE SALUD CARLOS III. 01/01/2022-31/12/2024

Next Generation-UEMnisterio de Ciencia e InnovaciónInstituto de Salud Carlos IIIPlan de Recuperación, transformación y Resiliencia
Ver Todos

Convenios/Contratos OTC (61)

Consultas, actos terapéuticos y cirugías complejas en el campo de la oftalmología, servicios de optometría, servicios actividad de genética, servicios de apoyo de enfermería en atención a consultas y adaptación de lentes de contacto. Servicios de enfermería en gestión de proyectos clínicos. Servicios de Patología. . Equipo Investigadores: MALDONADO LÓPEZ, MIGUEL JOSÉ (IP); LOPEZ MIGUEL, ALBERTO; GONZÁLEZ GARCÍA, MARÍA JESÚS; CALONGE CANO, MARGARITA; SOBAS ABAD, EVA MARIA; HERRERAS CANTALAPIEDRA, JOSE MARIA; COCO MARTIN, ROSA MARIA; MARTIN HERRANZ, RAUL; TELLERIA ORRIOLS, JUAN JOSE; PEREZ SOTO, MARIA INMACULADA. Entidades Participantes: FUNDACION GENERAL DE LA UNIVERSIDAD DE VALLADOLID.. Entidades Financiadoras: FUNDACION UNIVERSIDAD DE VALLADOLID.. 01/02/2024

Ver Todos

Otras ayudas y becas (2)

CONTRATO PREDOCTORAL JUNTA CASTILLA Y LEÓN DE KEVIN LOUIS PUERTAS NEYRA: "Protocolo estudio clínico; aceite de silicona; Siobal". COCO MARTIN, ROSA MARIA (Director). PUERTAS NEYRA, KEVIN LOUIS (Beneficiario). 01/08/2021 - 31/05/2025. 94.299,99 EUR.

JCYL-2FSE
Ver Todos
 

OTROS

Tesis doctorales (4)


 
Ver Todos

Congresos (1)

AYUDAS UVA A LA INVESTIGACION: ARVO 2008, FLORIDA ( ESTADOS UNIDOS DE AMÉRICA ) 27/04/2008 -
(Asistencia). COCO MARTIN, ROSA MARIA. AYUDAS UVA A LA INVESTIGACION: ARVO 2008
Ver Todos

Patentes (2)

Girish Kumar Srivastava, Mª Luz Alonso Alonso, Iván Fernández Bueno, Mª Teresa García Gutiérrez, Rosa Mª Coco Martín, José Carlos Pastor Jimeno. Método para determinar la citotoxicidad de sustancias químicas. P-201630708. 2016
Ver Todos

Estancias de investigación (1)

ASISTENCIA AL 22 EURETINA CONGRESO.. 01/09/2022 - 04/09/2022
     ASISTENCIA A CONGRESOS. ( ALEMANIA )


Ver Todos

Proyectos de innovación docente (6)

Píldoras de conocimiento para la descripción de técnicas de rehabilitación en pacientes con discapacidad visual. - PID2018/90. Universidad de Valladolid. 01/09/2018.
Ver Todos

Cátedras (1)

CÁTEDRA ZEISS EN LA UNIVERSIDAD DE VALLADOLID. Comisión Mixta Seguimiento: PASTOR BARAJAS, JOSE MARIA (Director); FERNANDEZ BUENO, IVAN; HERRERAS CANTALAPIEDRA, JOSE MARIA; USSA HERRERA, FERNANDO; JUBERIAS SANCHEZ, JOSE RAMON; COCO MARTIN, ROSA MARIA. Entidades Participantes: CARL ZEISS MEDITEC IBERIA SAU. 01/09/2017
Ver Todos
Cargando información ...
Universidad de Valladolid - Copyright Universidad de Valladolid - Todos los derechos reservados